Advertisement

Defects in Innate Immunity: Receptors and Signaling Components

  • Melinda ErdősEmail author
  • László Maródi
  • Seyed Alireza Mahdaviani
  • Sergio D. Rosenzweig
  • Joachim Roesler
  • Nima Rezaei
Chapter

Abstract

The innate immune system is the first-line host defense against microbial pathogens and is mediated by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and nucleotide-binding and oligomerization domain (NOD)-like receptors (NLR). PRPs consist of secreted and circulating proteins, and intracellular and transmembrane signal-transducing components [1]. They recognize pathogen-associated molecular patterns (PAMPs).

Keywords

Invasive Pneumococcal Disease Primary Immunodeficiency Disease IL12RB1 Gene Severe Chronic Neutropenia Whim Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Medzhitov R, Janeway CA Jr (1997) Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9(1):4–9PubMedCrossRefGoogle Scholar
  2. 2.
    Medzhitov R, Janeway CA Jr (2002) Decoding the patterns of self and nonself by the innate immune system. Science 296(5566):298–300PubMedCrossRefGoogle Scholar
  3. 3.
    Cottle LE (2011) Mendelian susceptibility to mycobacterial disease. Clin Genet 79(1):17–22PubMedCrossRefGoogle Scholar
  4. 4.
    Picard C, von Bernuth H, Ku CL, Yang K, Puel A, Casanova JL (2007) Inherited human IRAK-4 deficiency: an update. Immunol Res 38(1–3):347–352PubMedCrossRefGoogle Scholar
  5. 5.
    Kawai T, Malech HL (2009) WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol 16(1):20–26PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, Casanova JL (2008) Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev 226:29–40PubMedCrossRefGoogle Scholar
  7. 7.
    Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bustamante J, Breiman A, Altare F, Baretto R, Le Deist F, Kayal S, Koch H, Richter D, Brezina M, Aksu G, Wood P, Al-Jumaah S, Raspall M, Da Silva Duarte AJ, Tuerlinckx D, Virelizier JL, Fischer A, Enright A, Bernhoft J, Cleary AM, Vermylen C, Rodriguez-Gallego C, Davies G, Blutters-Sawatzki R, Siegrist CA, Ehlayel MS, Novelli V, Haas WH, Levy J, Freihorst J, Al-Hajjar S, Nadal D, De Vasconcelos Moraes D, Jeppsson O, Kutukculer N, Frecerova K, Caragol I, Lammas D, Kumararatne DS, Abel L, Casanova JL (2003) Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med 197(4):527–535PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenzweig S, Dorman SE, Roesler J, Palacios J, Zelazko M, Holland SM (2002) 561del4 defines a novel small deletion hotspot in the interferon-gamma receptor 1 chain. Clin Immunol 102(1):25–27PubMedCrossRefGoogle Scholar
  9. 9.
    Rosenzweig SD, Dorman SE, Uzel G, Shaw S, Scurlock A, Brown MR, Buckley RH, Holland SM (2004) A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol 173(6):4000–4008PubMedGoogle Scholar
  10. 10.
    Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, Yang K, Chapgier A, Eidenschenk C, Eid P, Al Ghonaium A, Tufenkeji H, Frayha H, Al-Gazlan S, Al-Rayes H, Schreiber RD, Gresser I, Casanova JL (2003) Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 33(3):388–391PubMedCrossRefGoogle Scholar
  11. 11.
    Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, Baretto R, Rosenzweig SD, Newport M, Levin M, Roesler J, Kumararatne D, Casanova JL, Holland SM (2004) Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364(9451):2113–2121PubMedCrossRefGoogle Scholar
  12. 12.
    Yancoski J, Rocco C, Bernasconi A, Oleastro M, Bezrodnik L, Vratnica C, Haerynck F, Rosenzweig SD (2009) A 475 years-old founder effect involving IL12RB1: a highly prevalent mutation conferring Mendelian Susceptibility to Mycobacterial Diseases in European descendants. Infect Genet Evol 9(4):574–580PubMedCrossRefGoogle Scholar
  13. 13.
    Staretz-Haham O, Melamed R, Lifshitz M, Porat N, Fieschi C, Casanova JL, Levy J (2003) Interleukin-12 receptor beta1 deficiency presenting as recurrent Salmonella infection. Clin Infect Dis 37(1):137–140PubMedCrossRefGoogle Scholar
  14. 14.
    Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, Takada H, Hara T, Kawamura N, Ariga T, Kaneko H, Kondo N, Tsuge I, Yachie A, Sakiyama Y, Iwata T, Bessho F, Ohishi T, Joh K, Imai K, Kogawa K, Shinohara M, Fujieda M, Wakiguchi H, Pasic S, Abinun M, Ochs HD, Renner ED, Jansson A, Belohradsky BH, Metin A, Shimizu N, Mizutani S, Miyawaki T, Nonoyama S, Karasuyama H (2006) Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25(5):745–755PubMedCrossRefGoogle Scholar
  15. 15.
    Hanson EP, Monaco-Shawver L, Solt LA, Madge LA, Banerjee PP, May MJ, Orange JS (2008) Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol 122(6):1169–1177, e1116PubMedCrossRefGoogle Scholar
  16. 16.
    Han TI, Kim IO, Kim WS, Yeon KM (2000) Disseminated BCG infection in a patient with severe combined immunodeficiency. Korean J Radiol 1(2):114–117PubMedCrossRefGoogle Scholar
  17. 17.
    Kroger L, Korppi M, Brander E, Kroger H, Wasz-Hockert O, Backman A, Rapola J, Launiala K, Katila ML (1995) Osteitis caused by bacille Calmette-Guerin vaccination: a retrospective analysis of 222 cases. J Infect Dis 172(2):574–576PubMedCrossRefGoogle Scholar
  18. 18.
    Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, Andrasofszky B, Lugosi L, Vadasz I, Mihailescu P et al (1988) Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 63(2):47–59PubMedGoogle Scholar
  19. 19.
    Milstien JB, Gibson JJ (1990) Quality control of BCG by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull World Health Organ 68:93–108PubMedGoogle Scholar
  20. 20.
    Fine PEM, Carneiro IAM, Milstien JB, Clements CJ (1999) Issues relating to the use of BCG immunization programmes—a discussion document. World Health Organization (WHO) document WHO/V&B/9923. WHO, GenevaGoogle Scholar
  21. 21.
    Romanus V, Fasth A, Tordai P, Wiholm BE (1993) Adverse reactions in healthy and immunocompromised children under six years of age vaccinated with the Danish BCG vaccine, strain Copenhagen 1331: implications for the vaccination policy in Sweden. Acta Paediatr 82(12):1043–1052PubMedCrossRefGoogle Scholar
  22. 22.
    Al-Arabi KM, Al-Khider ME, Sadiq S (1984) Osteitis of the humerus following BCG vaccination. Tubercle 65(4):305–307PubMedCrossRefGoogle Scholar
  23. 23.
    Krepela V, Galliova J, Kubec V, Marik J (1992) The effect of reduced doses of BCG vaccine on the occurrence of osseous complications after vaccination. Cesk Pediatr 47(3):134–136PubMedGoogle Scholar
  24. 24.
    Banac S, Franulovic J (1997) Familial liability to complications after BCG vaccination. Acta Paediatr 86(8):899–902PubMedCrossRefGoogle Scholar
  25. 25.
    Talbot EA, Perkins MD, Silva SF, Frothingham R (1997) Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 24(6):1139–1146PubMedCrossRefGoogle Scholar
  26. 26.
    Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, Gie RP, Cotton MF, van Helden PD, Warren RM, Beyers N (2006) Bacille Calmette-Guerin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 42(4):548–558PubMedCrossRefGoogle Scholar
  27. 27.
    Reichenbach J, Rosenzweig S, Doffinger R, Dupuis S, Holland SM, Casanova JL (2001) Mycobacterial diseases in primary immunodeficiencies. Curr Opin Allergy Clin Immunol 1(6):503–511PubMedCrossRefGoogle Scholar
  28. 28.
    Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S, Altare F, Stephan JL, Bernaudin F, Bordigoni P, Turck D, Lachaux A, Albertini M, Bourrillon A, Dommergues JP, Pocidalo MA, Le Deist F, Gaillard JL, Griscelli C, Fischer A (1996) Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study. Pediatrics 98(4 Pt 1):774–778PubMedGoogle Scholar
  29. 29.
    Bahri I, Boudawara T, Makni S, Kharrat M, Triki A, Ben H, Jlidi R (2001) Disseminated BCG infection: a four case study. Med Mal Infect 31:519–553Google Scholar
  30. 30.
    Remus N, Reichenbach J, Picard C, Rietschel C, Wood P, Lammas D, Kumararatne DS, Casanova JL (2001) Impaired interferon gamma-mediated immunity and susceptibility to mycobacterial infection in childhood. Pediatr Res 50(1):8–13PubMedCrossRefGoogle Scholar
  31. 31.
    McKusick VA (1998) Mendelian inheritance in man: catalogs of human genes and genetic disorders. Johns Hopkins University Press, Baltimore, MDGoogle Scholar
  32. 32.
    Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg J, Jouanguy E, Boisson-Dupuis S, Fieschi C, Picard C, Casanova JL (2006) Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 18(6):347–361PubMedCrossRefGoogle Scholar
  33. 33.
    Farrar MA, Schreiber RD (1993) The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571–611PubMedCrossRefGoogle Scholar
  34. 34.
    Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of ­signals, mechanisms and functions. J Leukoc Biol 75(2):163–189PubMedCrossRefGoogle Scholar
  35. 35.
    Schreiber RD, Farrar MA (1993) The biology and biochemistry of interferon-gamma and its receptor. Gastroenterol Jpn 28(Suppl 4):88–94, discussion 95–86PubMedGoogle Scholar
  36. 36.
    Bach EA, Aguet M, Schreiber RD (1997) The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 15:563–591PubMedCrossRefGoogle Scholar
  37. 37.
    Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264PubMedCrossRefGoogle Scholar
  38. 38.
    Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA (2005) Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33(Database issue):D514–D517PubMedCrossRefGoogle Scholar
  39. 39.
    Levin M, Newport MJ, D’Souza S, Kalabalikis P, Brown IN, Lenicker HM, Agius PV, Davies EG, Thrasher A, Klein N et al (1995) Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? Lancet 345(8942):79–83PubMedCrossRefGoogle Scholar
  40. 40.
    Casanova JL, Jouanguy E, Lamhamedi S, Blanche S, Fischer A (1995) Immunological conditions of children with BCG disseminated infection. Lancet 346(8974):581PubMedCrossRefGoogle Scholar
  41. 41.
    Dorman SE, Holland SM (2000) Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 11(4):321–333PubMedCrossRefGoogle Scholar
  42. 42.
    Casanova JL, Abel L (2002) Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 20:581–620PubMedCrossRefGoogle Scholar
  43. 43.
    Alcais A, Fieschi C, Abel L, Casanova JL (2005) Tuberculosis in children and adults: two distinct genetic diseases. J Exp Med 202(12):1617–1621PubMedCrossRefGoogle Scholar
  44. 44.
    MacLennan C, Fieschi C, Lammas DA, Picard C, Dorman SE, Sanal O, MacLennan JM, Holland SM, Ottenhoff TH, Casanova JL, Kumararatne DS (2004) Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis 190(10):1755–1757PubMedCrossRefGoogle Scholar
  45. 45.
    Picard C, Fieschi C, Altare F, Al-Jumaah S, Al-Hajjar S, Feinberg J, Dupuis S, Soudais C, Al-Mohsen IZ, Genin E, Lammas D, Kumararatne DS, Leclerc T, Rafii A, Frayha H, Murugasu B, Wah LB, Sinniah R, Loubser M, Okamoto E, Al-Ghonaium A, Tufenkeji H, Abel L, Casanova JL (2002) Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet 70(2):336–348PubMedCrossRefGoogle Scholar
  46. 46.
    Roesler J, Kofink B, Wendisch J, Heyden S, Paul D, Friedrich W, Casanova JL, Leupold W, Gahr M, Rosen-Wolff A (1999) Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol 27(9):1368–1374PubMedCrossRefGoogle Scholar
  47. 47.
    Moraes-Vasconcelos D, Grumach AS, Yamaguti A, Andrade ME, Fieschi C, de Beaucoudrey L, Casanova JL, Duarte AJ (2005) Paracoccidioides brasiliensis disseminated disease in a patient with inherited deficiency in the beta1 subunit of the interleukin (IL)-12/IL-23 receptor. Clin Infect Dis 41(4):e31–e37PubMedCrossRefGoogle Scholar
  48. 48.
    Zerbe CS, Holland SM (2005) Disseminated histoplasmosis in persons with interferon-gamma receptor 1 deficiency. Clin Infect Dis 41(4):e38–e41PubMedCrossRefGoogle Scholar
  49. 49.
    Sanal O, Turkkani G, Gumruk F, Yel L, Secmeer G, Tezcan I, Kara A, Ersoy F (2007) A case of interleukin-12 receptor beta-1 deficiency with recurrent leishmaniasis. Pediatr Infect Dis J 26(4):366–368PubMedCrossRefGoogle Scholar
  50. 50.
    Camcioglu Y, Picard C, Lacoste V, Dupuis S, Akcakaya N, Cokura H, Kaner G, Demirkesen C, Plancoulaine S, Emile JF, Gessain A, Casanova JL (2004) HHV-8-associated Kaposi sarcoma in a child with IFNgammaR1 deficiency. J Pediatr 144(4):519–523PubMedCrossRefGoogle Scholar
  51. 51.
    Rezaei N, Bonilla FA, Sullivan KE, de Vries E, Orange JS (2008) An introduction to primary immunodeficiency diseases. In: Rezaei N, Aghamohammadi A, Notarangelo LD (eds) Primary immunodeficiency diseases. Springer, Berlin HeidelbergCrossRefGoogle Scholar
  52. 52.
    de Vries E (2006) Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists. Clin Exp Immunol 145(2):204–214PubMedCrossRefGoogle Scholar
  53. 53.
    Slatter MA, Gennery AR (2008) Clinical immunology review series: an approach to the patient with recurrent infections in childhood. Clin Exp Immunol 152(3):389–396PubMedCrossRefGoogle Scholar
  54. 54.
    Al-Muhsen S, Casanova JL (2008) The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 122(6):1043–1051, quiz 1052–1043PubMedCrossRefGoogle Scholar
  55. 55.
    Lichtenauer-Kaligis EG, de Boer T, Verreck FA, van Voorden S, Hoeve MA, van de Vosse E, Ersoy F, Tezcan I, van Dissel JT, Sanal O, Ottenhoff TH (2003) Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency. Eur J Immunol 33(1):59–69PubMedCrossRefGoogle Scholar
  56. 56.
    Sanal O, Turul T, De Boer T, Van de Vosse E, Yalcin I, Tezcan I, Sun C, Memis L, Ottenhoff TH, Ersoy F (2006) Presentation of interleukin-12/-23 receptor beta1 deficiency with various clinical symptoms of Salmonella infections. J Clin Immunol 26(1):1–6PubMedCrossRefGoogle Scholar
  57. 57.
    Emile JF, Patey N, Altare F, Lamhamedi S, Jouanguy E, Boman F, Quillard J, Lecomte-Houcke M, Verola O, Mousnier JF, Dijoud F, Blanche S, Fischer A, Brousse N, Casanova JL (1997) Correlation of granuloma structure with clinical outcome defines two types of idiopathic ­disseminated BCG infection. J Pathol 181(1):25–30PubMedCrossRefGoogle Scholar
  58. 58.
    Altare F, Jouanguy E, Lamhamedi S, Doffinger R, Fischer A, Casanova JL (1998) Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 10(4):413–417PubMedCrossRefGoogle Scholar
  59. 59.
    Picard C, Baud O, Fieschi C, Casanova JL (2000) Diagnosis and management of inheritable disorders of interferon-g-mediated immunity. Immunol Allergy Clin North Am 20:65–76CrossRefGoogle Scholar
  60. 60.
    Rosenzweig SD, Holland SM (2004) Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 113(4):620–626PubMedCrossRefGoogle Scholar
  61. 61.
    Chapgier A, Boisson-Dupuis S, Jouanguy E, Vogt G, Feinberg J, Prochnicka-Chalufour A, Casrouge A, Yang K, Soudais C, Fieschi C, Santos OF, Bustamante J, Picard C, de Beaucoudrey L, Emile JF, Arkwright PD, Schreiber RD, Rolinck-Werninghaus C, Rosen-Wolff A, Magdorf K, Roesler J, Casanova JL (2006) Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet 2(8):e131PubMedCrossRefGoogle Scholar
  62. 62.
    Sorensen RU, Leiva LE, Javier FC 3rd, Sacerdote DM, Bradford N, Butler B, Giangrosso PA, Moore C (1998) Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 102(2):215–221PubMedCrossRefGoogle Scholar
  63. 63.
    Sorensen RU, Leiva LE, Giangrosso PA, Butler B, Javier FC 3rd, Sacerdote DM, Bradford N, Moore C (1998) Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J 17(8):685–691PubMedCrossRefGoogle Scholar
  64. 64.
    Picard C, Puel A, Bustamante J, Ku CL, Casanova JL (2003) Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 3(6):451–459PubMedCrossRefGoogle Scholar
  65. 65.
    Wurzner R (2003) Complement and infectious diseases. Contrib Microbiol 10:1–17PubMedCrossRefGoogle Scholar
  66. 66.
    Ku CL, Picard C, Erdos M, Jeurissen A, Bustamante J, Puel A, von Bernuth H, Filipe-Santos O, Chang HH, Lawrence T, Raes M, Marodi L, Bossuyt X, Casanova JL (2007) IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet 44(1):16–23PubMedCrossRefGoogle Scholar
  67. 67.
    Jiao H, Toth B, Erdos M, Fransson I, Rakoczi E, Balogh I, Magyarics Z, Derfalvi B, Csorba G, Szaflarska A, Megarbane A, Akatcherian C, Dbaibo G, Rajnavolgyi E, Hammarstrom L, Kere J, Lefranc G, Marodi L (2008) Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol 46(1):202–206PubMedCrossRefGoogle Scholar
  68. 68.
    Wolpert J, Knutsen AP (1998) Natural history of selective antibody deficiency to bacterial polysaccharide antigens in children. Pediatr Asthma Allergy Immunol 12:183–191CrossRefGoogle Scholar
  69. 69.
    Gorlin RJ, Gelb B, Diaz GA, Lofsness KG, Pittelkow MR, Fenyk JR Jr (2000) WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies. Am J Med Genet 91(5):368–376PubMedCrossRefGoogle Scholar
  70. 70.
    Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, Francois F, Klotman ME, Diaz GA (2003) Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 34(1):70–74PubMedCrossRefGoogle Scholar
  71. 71.
    Alapi K, Erdos M, Kovacs G, Marodi L (2007) Recurrent CXCR4 sequence variation in a girl with WHIM syndrome. Eur J Haematol 78(1):86–88PubMedCrossRefGoogle Scholar
  72. 72.
    Nagasawa T, Tachibana K, Kishimoto T (1998) A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol 10(3):179–185PubMedCrossRefGoogle Scholar
  73. 73.
    Gulino AV, Moratto D, Sozzani S, Cavadini P, Otero K, Tassone L, Imberti L, Pirovano S, Notarangelo LD, Soresina R, Mazzolari E, Nelson DL, Badolato R (2004) Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 104(2):444–452PubMedCrossRefGoogle Scholar
  74. 74.
    Kawai T, Choi U, Whiting-Theobald NL, Linton GF, Brenner S, Sechler JM, Murphy PM, Malech HL (2005) Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol 33(4):460–468PubMedCrossRefGoogle Scholar
  75. 75.
    Diaz GA (2005) CXCR4 mutations in WHIM syndrome: a misguided immune system? Immunol Rev 203:235–243PubMedCrossRefGoogle Scholar
  76. 76.
    Hord JD, Whitlock JA, Gay JC, Lukens JN (1997) Clinical features of myelokathexis and treatment with hematopoietic cytokines: a case report of two patients and review of the literature. J Pediatr Hematol Oncol 19(5):443–448PubMedCrossRefGoogle Scholar
  77. 77.
    Goddard EA, Hughes EJ, Beatty DW (1994) A case of immunodeficiency characterized by neutropenia, hypogammaglobulinaemia, recurrent infections and warts. Clin Lab Haematol 16(3):297–302PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Melinda Erdős
    • 1
    Email author
  • László Maródi
    • 1
  • Seyed Alireza Mahdaviani
    • 2
  • Sergio D. Rosenzweig
    • 3
  • Joachim Roesler
    • 4
  • Nima Rezaei
    • 5
    • 6
    • 7
  1. 1.Department of Infectious and Pediatric ImmunologyMedical and Health Science Center, University of DebrecenDebrecenHungary
  2. 2.Pediatric Respiratory Disease Research CenterNational Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti Medical UniversityTehranIran
  3. 3.Primary Immunodeficiency Clinic, Laboratory of Host DefensesNIAID, National Institute of HealthBethesdaUSA
  4. 4.Department of PediatricsUniversity HospitalDresdenGermany
  5. 5.Department of ImmunologyResearch Center for Immunodeficiencies, Children’s Medical Center HospitalTehranIran
  6. 6.Molecular Immunology Research CenterTehranIran
  7. 7.Department of Immunology, School of MedicineTehran University of Medical SciencesTehranIran

Personalised recommendations